Cellular and Molecular Life Sciences CMLS

, Volume 61, Issue 23, pp 2932–2938

Oncogenic protein tyrosine kinases

Normal and oncogenic FLT3
Multi-author Review

DOI: 10.1007/s00018-004-4274-x

Cite this article as:
Naoe, T. & Kiyoi, H. CMLS, Cell. Mol. Life Sci. (2004) 61: 2932. doi:10.1007/s00018-004-4274-x

Abstract.

FLT3, a member of the class III receptor tyrosine kinases (RTKs), is preferentially expressed on the cell surface of hematopoietic progenitors, and the ligand of FLT3 (FL) is expressed as a membrane-bound or soluble form by bone marrow stroma cells. It has been disclosed that FL-FLT3 interaction plays an important role in the maintenance, proliferation and differentiation of hematopoiesis. FLT3 is also expressed in a high proportion of acute myeloid leukemia (AML) and B-lineage acute lymphoblastic leukemia cells. Activating mutations of FLT3 are the most frequent genetic lesions in AML, and AML patients with FLT3 mutations have a worse prognosis than those with normal FLT3. Exploring the mechanism by which FLT3 mutations cause autoactivation and uncontrolled signaling might lead to a better understanding of how FLT3 becomes oncogenic and provide insights for the development of new drugs.

Key words.

FLT3 tyrosine kinase hematopoiesis leukemia tandem duplication point mutation target therapy kinase inhibitor 

Copyright information

© Birkhäuser Verlag, Basel 2004

Authors and Affiliations

  1. 1.Department of Hematology, Graduate School of MedicineNagoya UniversityNagoyaJapan
  2. 2.Department of Infectious Diseases, Graduate School of MedicineNagoya UniversityNagoyaJapan

Personalised recommendations